Breast cancer pathological diagnosis reveals correlation between progesterone receptor membrane component 1 and clinicopathological parameters

doi:10.3969/j.issn.1006-7795.2022.03.004

Abstract

Abstract: Objective To explore the correlation between progesterone receptor membrane component 1 (PGRMC1) and malignant proliferation of breast cancer. Methods The expression of PGRMC1 was detected immunohistochemically in 90 specimens of breast cancer (the median age was 47), 60 benign breast diseases (the median age was 45) and 60 cases of normal breast tissues from September 2017 to January 2019. All of them were women, and all tissues were diagnosed by the hollow needle biopsy or postoperative histologic examination. As a research project, all participants signed informed consent voluntarily.The pathological grade of breast cancer was determined viahematoxylin-eosin staining to determine. The association of PGRMC1 with pathological factors and the expression of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (Her-2), nuclear-associated antigen (Ki-67) was assessed. Results Positive expression of PGRMC1 was 63.33% (57/90) in breast cancer, 28.33% (17/60) in benign breast diseases and 6.67% (4/60) in normal breast tissues. PGRMC1 expression was significantly correlated to tumor size, lymphatic metastasis and the histological grade (P<0.001, respectively), PGRMC1 positive expression rate increased with the increase of histological grade of breast cancer, but not significantly correlated with menstruation in breast cancer (P>0.05). The expression of PGRMC1 in breast cancer group was related to the expression of ER, Ki-67, PR and Her-2 (P<0.05), which was most closely related to ER (r=0.461), followed by Ki-67 (r=0.330), but weakly correlated with the expression of PR and Ki-67(r=0.132,r=0.103, respectively). The expression of PGRMC1 in benign breast disease group was related to the expression of Ki-67 and Her-2 (P<0.05), and the correlation with the expression of Ki-67 (r=0.569) was higher than that of Her-2 (r=0.228). Conclusion PGRMC1 is highly expressed in breast cancer. PGRMC1 expression is strongly associated with the biological behavior of breast cancer. It may serve as a useful prognostic indicator of the malignancy. Meanwhile, it is found that PGRMC1 is closely related to ER expression in breast cancer, suggesting that PGRMC1 may potentiate estrogen signaling.

Key words: menopausal hormone therapy, progesterone receptor membrane component 1, breast cancer, benign breast diseases, immunohistochemistry

CLC Number:

R737.9

Zhao Yue, Ruan Xiangyan, Cheng Jiaojiao, Gu Muqing, Xu Xin, Wang Yuejiao. Breast cancer pathological diagnosis reveals correlation between progesterone receptor membrane component 1 and clinicopathological parameters[J]. Journal of Capital Medical University, 2022, 43(3): 350-356.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2022.03.004

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2022/V43/I3/350

References

[1] Rozenberg S, Al-Daghri N, Aubertin-Leheudre M, et al. Is there a role for menopausal hormone therapy in the management of postmenopausal osteoporosis?[J]. Osteoporos Int, 2020, 31(12): 2271-2286.
[2] Yong E L, Logan S. Menopausal osteoporosis: screening, prevention and treatment[J]. Singapore Med J, 2021, 62(4): 159-166.
[3] Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence[J]. Lancet, 2019, 394(10204): 1159-1168.
[4] Cao M M, Li H, Sun D Q, et al. Cancer burden of major cancers in China: a need for sustainable actions[J]. Cancer Commun (Lond), 2020, 40(5): 205-210.
[5] Wei Y X, Lv J, Guo Y, et al. Soy intake and breast cancer risk: a prospective study of 300,000 Chinese women and a dose-response meta-analysis[J]. Eur J Epidemiol, 2020, 35(6): 567-578.
[6] Sopik V. International variation in breast cancer incidence and mortality in young women[J]. Breast Cancer Res Treat, 2021, 186(2): 497-507.
[7] Zhao Y, Ruan X Y. Identification of PGRMC1 as a candidate oncogene for head and neck cancers and its involvement in metabolic activities[J]. Front Bioeng Biotechnol, 2019, 7: 438.
[8] 赵越, 阮祥燕, 张泉东, 等. 乳腺癌患者血液中PGRMC1浓度与临床相关性[J]. 首都医科大学学报, 2018, 39(4): 486-493.
[9] 赵越, 程姣姣. 孕激素受体膜组分1对激素诱导下乳腺癌增殖影响的实验研究[J]. 中国医药导报, 2019, 16(34): 11-14, 182.
[10] Zhao Y, Ruan X Y, Wang H S, et al. The presence of a membrane-bound progesterone receptor induces growth of breast cancer with norethisterone but not with progesterone: a xenograft model[J]. Maturitas, 2017, 102: 26-33.
[11] Finkelman B S, Meindl A, LaBoy C, et al. Correlation of manual semi-quantitative and automated quantitative Ki-67 proliferative index with OncotypeDX^TM recurrence score in invasive breast carcinoma[J]. Breast Dis, 2022, 41(1): 55-65.
[12] Teichgraeber D C, Guirguis M S, Whitman G J. Breast cancer staging: updates in the AJCC Cancer Staging Manual, 8th edition, and current challenges for radiologists, from the AJR special series on cancer staging[J]. AJR Am J Roentgenol, 2021, 217(2): 278-290.
[13] Tan P H, Ellis I, Allison K, et al. The 2019 World Health Organization classification of tumours of the breast[J]. Histopathology, 2020, 77(2): 181-185.
[14] Deli T, Orosz M, Jakab A. Hormone replacement therapy in cancer survivors-review of the literature[J]. Pathol Oncol Res, 2020, 26(1): 63-78.
[15] Santen R J, Heitjan D F, Gompel A, et al. Underlying breast cancer risk and menopausal hormone therapy[J]. J Clin Endocrinol Metab, 2020, 105(6): dgaa073.
[16] Ramchand S K, Cheung Y M, Yeo B, et al. The effects of adjuvant endocrine therapy on bone health in women with breast cancer[J]. J Endocrinol, 2019, 241(3): R111-R124.
[17] Li X, Ruan X, Gu M, et al. PGRMC1 can trigger estrogen-dependent proliferation of breast cancer cells: estradiol vs. equilin vs. ethinylestradiol[J]. Climacteric, 2019, 22(5): 483-488.
[18] Ruan X Y, Gu M Q, Cai G J, et al. Progestogens and PGRMC1-dependent breast cancer tumor growth: an in-vitro and xenograft study[J]. Maturitas, 2019, 123: 1-8.
[19] Rüschoff J, Nagelmeier I, Jasani B, et al. ISH-based HER2 diagnostics[J]. Pathologe, 2021, 42(Suppl 1): 62-68.